The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma

(2014) L. Liu et al.   CLINICAL CANCER RESEARCH

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients

(2013) Y. Zhao et al.   ANNALS OF ONCOLOGY

Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments

(2013) Riad Salem et al.   JOURNAL OF HEPATOLOGY

Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

(2013) Xin-Sen Xu   WORLD JOURNAL OF GASTROENTEROLOGY

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

(2012) Joong-Won Park et al.   JOURNAL OF HEPATOLOGY

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

(2012) Nicola Personeni et al.   JOURNAL OF HEPATOLOGY

Management of HCC

(2012) Carlos Rodríguez de Lope et al.   JOURNAL OF HEPATOLOGY

Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?

(2012) Christos Georgiades et al.   RADIOLOGY

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma

(2011) Timothy M. Pawlik et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models

(2011) Ju Hyun Shim et al.   RADIOLOGY

Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

(2011) Nikolaus Kohles et al.   TUMOR BIOLOGY

Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

(2010) Ming-Chao Tsai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization

(2009) Ahsun Riaz et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival

(2009) Ahsun Riaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres

(2008) Ahsun Riaz et al.   HEPATOLOGY

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

(2008) Stephen L. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE